Chong Kun Dang Pharmaceutical Corp. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of cardiovascular, endocrine, immunological, psychiatric, renal, inflammatory disorders, metabolic diseases and neurodegeneration.
Mainly expressed in the liver, microRNA‑122‑5p (miR‑122) exhibits increased circulating levels in the context of obesity. When elevated in the bloodstream, miR-122 can act on extrahepatic tissues, including vascular endothelial cells, where it contributes to endothelial dysfunction and may promote the development of diabetic vascular complications.
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead.
Interax Biotech Ltd. and Alveus Therapeutics Inc. have signed a strategic research collaboration and licensing agreement to develop a differentiated small-molecule candidate for metabolic disease. Designed to overcome the limitations of current obesity medications, the candidate is expected to deliver durable weight loss with superior tolerability.
Once it was considered to be more or less a passive energy-storing device that could double as a cushion. But increasingly, fat is conceptualized as an endocrine organ as much as a tissue type. Now, separate research groups have reported new insights into the functional roles of different fats based on their anatomical location and functional characteristics.
Biolexis Therapeutics Inc. has identified AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of diabetes, ischemia-reperfusion injury, dyslipidemia, obesity, Duchenne muscular dystrophy, metabolic dysfunction-associated steatotic liver disease, spinal muscular atrophy and Alzheimer's disease, among others.
Neurocrine Biosciences Inc. has disclosed chemically modified polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor (GCGR) and/or glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity.
Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S. FDA is acknowledging that the drugs don’t have the same risk seen with older weight-loss medicines. Citing its post-market evaluation that found no increased risk of suicidal ideation or behavior, the U.S. FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs – Eli Lilly and Co.’s Zepbound (tirzepatide) and Novo Nordisk A/S’ Saxenda (liraglutide) and Wegovy (semaglutide).
RSS
